Pfizer Beats Q3 Estimates, Raises FY26 Outlook, Names New CFO

Pfizer reported third-quarter results that topped expectations and lifted its full-year 2026 guidance, while simultaneously announcing a leadership change at the top of its finance function. The pharmaceutical giant named Cecile Guegan as its new chief financial officer, a transition disclosed alongside the earnings release. The combination of an earnings beat and a raised outlook signals that Pfizer's turnaround efforts are gaining traction, with management expressing greater confidence in the company's trajectory for the remainder of the year. For investors, the dual announcement is significant: the raised FY26 guidance suggests stronger-than-anticipated performance across the business, while the CFO appointment introduces a new steward of the company's capital allocation strategy at a pivotal moment. The market will be watching how Guegan shapes financial priorities, including pipeline investment and cost management, as Pfizer seeks to sustain momentum. Details on the magnitude of the beat and the specific guidance revision were not immediately available in the initial snapshot. Investors should monitor follow-up commentary from management on the earnings call and any further disclosure on the CFO transition timeline and strategic priorities.